Wanbury Limited (NSE:WANBURY)

Market Cap	8.84B
Revenue (ttm)	6.00B
Net Income (ttm)	305.30M
Shares Out	n/a
EPS (ttm)	8.98
PE Ratio	28.95
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,348
Average Volume	46,762
Open	266.00
Previous Close	268.90
Day's Range	260.00 - 272.00
52-Week Range	154.01 - 329.70
Beta	0.28
RSI	51.16
Earnings Date	Aug 8, 2025

About Chimerix

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 1,491
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WANBURY

Financial Performance

In 2024, Wanbury's revenue was 6.00 billion, an increase of 4.15% compared to the previous year's 5.76 billion. Earnings were 305.30 million, a decrease of -45.44%.